ANXA6 and cardiomyopathy: A controlled expression level (~3- to 4.5-fold increase over control) was essential as uncontrolled overexpression of Anxa6 resulted in cell death in our pilot experiments (data not shown) and, as reported by others, leads to the development of cardiomyopathies in animal models.19 Analysis of TMRM fluorescence levels indicated that mitochondrial ΔΨm was significantly more conserved during PE treatment in the H9c2Anxa6-EGFP cells compared with the control (H9c2EGFP) cells, especially during the first 24 h of treatment (Figure 6e).